PlainPharmaWatch

CMS Open Payments · Tool

4WEB, Inc. vs Astellas Pharma Global Development

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Astellas Pharma Global Development has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 386, versus 362 for the other company. Its single largest recorded recipient represents 11.3% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

4WEB, Inc.
HHI 362 · top recipient 10.1%
Ranked #1,407 of 1,838 companies by HHI
Astellas Pharma Global Development
HHI 386 · top recipient 11.3%
Ranked #1,382 of 1,838 companies by HHI

Payment Overview

Company A

4WEB, Inc.

Total Payments
$8.9M
% of Industry
0.1%
Transactions
748
Avg per Transaction
$12.0K
Recipients
718
Avg per Recipient
$12.5K
Payment Types
4
Top Payment Type
Consulting Fee
Total Payments
$8.9M
% of Industry
0.1%
Transactions
3,122
Avg per Transaction
$2.8K
Recipients
866
Avg per Recipient
$10.3K
Payment Types
4
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

4WEB, Inc. vs Astellas Pharma Global Development - total reported payments in CMS Open Payments PY2024

4WEB, Inc.$8.9MAstellas Pharma Global Deve…$8.9M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

4WEB, Inc.

Consulting Fee $53.6K

37.8%

Food and Beverage $47.7K

33.6%

Royalty or License $36.2K

25.5%

Travel and Lodging $4.4K

3.1%

Astellas Pharma Global Development

Consulting Fee $598.6K

90.4%

Food and Beverage $46.2K

7.0%

Travel and Lodging $16.9K

2.6%

Education $266.00

0.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

4WEB, Inc.

  1. 1

    Daniel M Williams

    $14,251.63 · 6 txns

  2. 2

    Steven Koufman Leckie

    $12,624.42 · 4 txns

  3. 3

    Rajesh V Patel

    $12,493.87 · 10 txns

  4. 4

    Brad Prybis

    $6,721.40 · 108 txns

  5. 5

    Abdul Arain

    $5,205.30 · 9 txns

Astellas Pharma Global Development

  1. 1

    National Jewish Health

    $75,000.00 · 1 txns

  2. 2

    Rush University Medical Center

    $70,000.00 · 1 txns

  3. 3

    DILRAJ S GREWAL

    $35,927.92 · 9 txns

  4. 4

    ELEONORA LAD

    $35,850.00 · 9 txns

  5. 5

    MICHAEL ALLINGHAM

    $29,050.00 · 7 txns

Summary Comparison

Metric 4WEB, Inc. Astellas Pharma Global Development
Total Payments $8.9M $8.9M
% of Industry Total 0.1% 0.1%
Transaction Count 748 3,122
Avg per Transaction $12.0K $2.8K
Recipient Count 718 866
Avg per Recipient $12.5K $10.3K
Payment Type Count 4 4
Top Payment Type Consulting Fee Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.